Overview

Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in Healthy Volunteers

Status:
Active, not recruiting
Trial end date:
2022-12-29
Target enrollment:
Participant gender:
Summary
This is a single center, two-period, randomized study to evaluate the bioequivalence of a single dose of tasimelteon capsule formulation relative to a single dose of liquid suspension formation in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Vanda Pharmaceuticals